利用药物成瘾机制筛选抗MAPKi耐药黑色素瘤
该研究探讨了MAPK抑制剂(MAPKi)耐药黑色素瘤在停药后的药物成瘾现象及其治疗利用。研究发现停药后pERK反弹可导致细胞周期减慢或细胞死亡,而药理学上损害DNA损伤修复可增强药物成瘾,将细胞周期减慢转化为caspase依赖性细胞死亡或促进parthanatos相关细胞死亡。在MEKi耐药的NRAS突变或非典型BRAF突变黑色素瘤中,I型RAF抑制剂可增强MEKi停药引发的pERK反弹,促进细胞死亡为主的药物成瘾表型。
要点
- MAPKi停药后pERK反弹可导致细胞周期减慢或细胞死亡,强反弹引发DNA损伤和parthanatos相关细胞死亡。
- 药理学损害DNA损伤修复可增强MAPKi成瘾,将细胞周期减慢转化为caspase依赖性细胞死亡。
- 在MEKi耐药的NRAS突变或非典型BRAF突变黑色素瘤中,I型RAF抑制剂增强pERK反弹并促进细胞死亡。
核心结论
- MAPKi耐药黑色素瘤在停药后表现出药物成瘾现象,利用该机制可筛选针对耐药克隆的治疗策略。
研究设计与样本
- 研究使用MAPKi耐药的BRAF突变或NRAS突变黑色素瘤模型,探讨停药后的药物成瘾机制。
主要发现
- 停药后pERK反弹通常上调p38-FRA1-JUNB-CDKN1A并下调增殖,但仅强pERK反弹导致DNA损伤和parthanatos相关细胞死亡。
- 药理学损害DNA损伤修复可将细胞周期减慢转化为caspase依赖性细胞死亡或进一步促进parthanatos相关细胞死亡。
- 在MEKi耐药的NRAS突变或非典型BRAF突变黑色素瘤中,I型RAF抑制剂增强MEKi停药引发的pERK反弹,促进细胞死亡为主的药物成瘾表型。
关键数值与推荐
- 停药后强pERK反弹导致DNA损伤和parthanatos相关细胞死亡。
- 药理学损害DNA损伤修复将细胞周期减慢转化为caspase依赖性细胞死亡或促进parthanatos相关细胞死亡。
- I型RAF抑制剂增强MEKi停药引发的pERK反弹,促进细胞死亡为主的药物成瘾表型。
临床怎么用
- 疾病进展后停用MAPKi应与增强MAPKi成瘾的特定策略相结合。
- 利用pERK超生理水平与DNA损伤之间的合成致死性,可合理化序贯/轮换方案以应对 evolving vulnerabilities。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Melanoma resistant to MAPK inhibitors (MAPKi) displays loss of fitness upon experimental MAPKi withdrawal and, clinically, may be resensitized to MAPKi therapy after a drug holiday. Here, we uncovered and therapeutically exploited the mechanisms of MAPKi addiction in MAPKi-resistant BRAFMUT or NRASMUT melanoma. MAPKi-addiction phenotypes evident upon drug withdrawal spanned transient cell-cycle slowdown to cell-death responses, the latter of which required a robust phosphorylated ERK (pERK) rebound. Generally, drug withdrawal-induced pERK rebound upregulated p38-FRA1-JUNB-CDKN1A and downregulated proliferation, but only a robust pERK rebound resulted in DNA damage and parthanatos-related cell death. Importantly, pharmacologically impairing DNA damage repair during MAPKi withdrawal augmented MAPKi addiction across the board by converting a cell-cycle deceleration to a caspase-dependent cell-death response or by furthering parthanatos-related cell death. Specifically in MEKi-resistant NRASMUT or atypical BRAFMUT melanoma, treatment with a type I RAF inhibitor intensified pERK rebound elicited by MEKi withdrawal, thereby promoting a cell death-predominant MAPKi-addiction phenotype. Thus, MAPKi discontinuation upon disease progression should be coupled with specific strategies that augment MAPKi addiction.Significance: Discontinuing targeted therapy may select against drug-resistant tumor clones, but drug-addiction mechanisms are ill-defined. Using melanoma resistant to but withdrawn from MAPKi, we defined a synthetic lethality between supraphysiologic levels of pERK and DNA damage. Actively promoting this synthetic lethality could rationalize sequential/rotational regimens that address evolving vulnerabilities. Cancer Discov; 8(1); 74-93. ©2017 AACR.See related commentary by Stern, p. 20This article is highlighted in the In This Issue feature, p. 1.
引用
- Hong A, Moriceau G, Sun L, et al. Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma. Cancer Discov. 2017. PMID: 28923912. doi:10.1158/2159-8290.CD-17-0682
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。